295 related articles for article (PubMed ID: 19819121)
1. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis.
Ma J; Yang W; Fang N; Zhu W; Wei M
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):596-603. PubMed ID: 19819121
[TBL] [Abstract][Full Text] [Related]
2. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials.
Mannucci E; Monami M; Lamanna C; Gori F; Marchionni N
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):604-12. PubMed ID: 19427768
[TBL] [Abstract][Full Text] [Related]
3. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
Castagno D; Baird-Gunning J; Jhund PS; Biondi-Zoccai G; MacDonald MR; Petrie MC; Gaita F; McMurray JJ
Am Heart J; 2011 Nov; 162(5):938-948.e2. PubMed ID: 22093212
[TBL] [Abstract][Full Text] [Related]
4. Impact of glycemic treatment choices on cardiovascular complications in type 2 diabetes.
Weiss IA; Valiquette G; Schwarcz MD
Cardiol Rev; 2009; 17(4):165-75. PubMed ID: 19525678
[TBL] [Abstract][Full Text] [Related]
5. Early and intensive therapy for management of hyperglycemia and cardiovascular risk factors in patients with type 2 diabetes.
Dailey G
Clin Ther; 2011 Jun; 33(6):665-78. PubMed ID: 21704233
[TBL] [Abstract][Full Text] [Related]
6. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials.
Tkác I
Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S57-62. PubMed ID: 20115934
[TBL] [Abstract][Full Text] [Related]
7. Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.
Akalin S; Berntorp K; Ceriello A; Das AK; Kilpatrick ES; Koblik T; Munichoodappa CS; Pan CY; Rosenthall W; Shestakova M; Wolnik B; Woo V; Yang WY; Yilmaz MT;
Int J Clin Pract; 2009 Oct; 63(10):1421-5. PubMed ID: 19769698
[TBL] [Abstract][Full Text] [Related]
8. Dosing of insulin glargine in the treatment of type 2 diabetes.
Barnett A
Clin Ther; 2007 Jun; 29(6):987-99. PubMed ID: 17692716
[TBL] [Abstract][Full Text] [Related]
9. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis.
Zhang CY; Sun AJ; Zhang SN; Wu CN; Fu MQ; Xia G; Wang KQ; Zou YZ; Ge JB
Ann Med; 2010 May; 42(4):305-15. PubMed ID: 20429797
[TBL] [Abstract][Full Text] [Related]
10. Effect of blood glucose concentrations on the development of chronic complications of diabetes mellitus.
Swidan SZ; Montgomery PA
Pharmacotherapy; 1998; 18(5):961-72. PubMed ID: 9758308
[TBL] [Abstract][Full Text] [Related]
11. Nicotinamide effects oxidative burst activity of neutrophils in patients with poorly controlled type 2 diabetes mellitus.
Osar Z; Samanci T; Demirel GY; Damci T; Ilkova H
Exp Diabesity Res; 2004; 5(2):155-62. PubMed ID: 15203886
[TBL] [Abstract][Full Text] [Related]
12. Controlling blood glucose levels in patients with type 2 diabetes mellitus. An evidence-based policy statement by the American Academy of Family Physicians and American Diabetes Association.
Woolf SH; Davidson MB; Greenfield S; Bell HS; Ganiats TG; Hagen MD; Palda VA; Rizza RA; Spann SJ
J Fam Pract; 2000 May; 49(5):453-60. PubMed ID: 10836779
[TBL] [Abstract][Full Text] [Related]
13. Glycemic control and complications in type 2 diabetes mellitus.
Stolar M
Am J Med; 2010 Mar; 123(3 Suppl):S3-11. PubMed ID: 20206730
[TBL] [Abstract][Full Text] [Related]
14. Sugar and stroke: cerebrovascular disease and blood glucose control.
Quinn TJ; Dawson J; Walters MR
Cardiovasc Ther; 2011 Dec; 29(6):e31-42. PubMed ID: 20491782
[TBL] [Abstract][Full Text] [Related]
15. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds.
Zoungas S; Chalmers J; Ninomiya T; Li Q; Cooper ME; Colagiuri S; Fulcher G; de Galan BE; Harrap S; Hamet P; Heller S; MacMahon S; Marre M; Poulter N; Travert F; Patel A; Neal B; Woodward M;
Diabetologia; 2012 Mar; 55(3):636-43. PubMed ID: 22186981
[TBL] [Abstract][Full Text] [Related]
16. Extent of glycemic control in type 2 diabetes mellitus: close, but no cigar.
Lerch C; Richter B
Nutr Metab Cardiovasc Dis; 2009 Nov; 19(9):593-5. PubMed ID: 19833492
[No Abstract] [Full Text] [Related]
17. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
[TBL] [Abstract][Full Text] [Related]
18. Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.
Terry T; Raravikar K; Chokrungvaranon N; Reaven PD
Curr Cardiol Rep; 2012 Feb; 14(1):79-88. PubMed ID: 22160862
[TBL] [Abstract][Full Text] [Related]
19. Intensive glucose lowering treatment in type 2 diabetes.
Preiss D; Ray KK
BMJ; 2011 Jul; 343():d4243. PubMed ID: 21791496
[No Abstract] [Full Text] [Related]
20. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials.
Ismail-Beigi F; Moghissi E; Tiktin M; Hirsch IB; Inzucchi SE; Genuth S
Ann Intern Med; 2011 Apr; 154(8):554-9. PubMed ID: 21502652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
